

DOI: 10.1113/EP087283

## **Plasma ferritin concentration is positively associated with *in vivo* fatty acid mobilization and insulin resistance in obese women**

Ryan BJ, Van Pelt DW, Guth LM, Ludzki AC, Gioscia-Ryan RA, Ahn C, Foug KL, Horowitz JF

Affiliation: Substrate Metabolism Laboratory, School of Kinesiology, University of Michigan, Ann Arbor, Michigan

Short Title: Iron, lipolysis, and insulin resistance in obesity

Corresponding Author

Jeffrey F. Horowitz, Ph.D.

School of Kinesiology, Univ. of Michigan, 401 Washtenaw Ave., Ann Arbor, MI 48109-2214

[jeffhoro@umich.edu](mailto:jeffhoro@umich.edu)

734-647-1076

Competing Interests: The authors have no competing interests to declare.

Funding Support: American Diabetes Association 1-16-ICTS-048; National Institutes of Health R01DK077966, T32DK007245, P30DK089503, UL1TR000433; Canadian Institutes of Health Research DFS 146190

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1113/EP087283](https://doi.org/10.1113/EP087283).

This article is protected by copyright. All rights reserved.

### **What is the central question of this study?**

Do obese women with relatively high whole-body iron stores exhibit elevated *in vivo* rates of fatty acid (FA) release from adipose tissue compared with a well-matched cohort of obese women with relatively low iron stores?

### **What is the main finding and its importance?**

Obese women with high plasma [ferritin] (a marker of whole-body iron stores) had greater FA mobilization, lipolytic activation in adipose tissue, and insulin resistance (IR) compared to obese women with lower plasma [ferritin]. As elevated FA mobilization is intimately linked with the development of IR, these findings suggest that elevated iron stores may contribute to IR in obesity by increasing systemic FA availability.

### **ABSTRACT**

High rates of fatty acid (FA) mobilization from adipose tissue are associated with insulin resistance (IR) in obesity. *In vitro* evidence suggests that iron stimulates lipolysis in adipocytes but whether iron is related to *in vivo* FA mobilization is unknown. We hypothesized that plasma ferritin concentration ([ferritin]), a marker of body iron stores, would be positively associated with FA mobilization. We measured [ferritin], FA rate of appearance into systemic circulation (FA Ra; stable isotope dilution), key adipose tissue lipolytic proteins, and IR (hyperinsulinemic-euglycemic clamp) in 20 obese, premenopausal women. [Ferritin] was correlated with FA Ra ( $r=0.65;p=0.002$ ) and IR ( $r=0.57;p=0.008$ ); these relationships remained significant after controlling for BMI and plasma [C-reactive protein] ([CRP], a marker of systemic inflammation) in multiple regression analyses. We then stratified subjects into tertiles based on [ferritin] to compare subjects with “High-ferritin” vs. “Low-

ferritin". Plasma [hepcidin] was more than 5-fold greater in High-ferritin vs. Low-ferritin ( $p < 0.05$ ) but there was no difference in plasma [CRP] between groups, indicating that the large difference in plasma [ferritin] reflects a difference in iron stores, not systemic inflammation. We found that FA Ra, adipose protein abundance of hormone sensitive lipase and adipose triglyceride lipase, and IR were significantly greater in High-ferritin vs. Low-ferritin (all  $p < 0.05$ ). These data provide the first evidence linking iron and *in vivo* FA mobilization and suggest that elevated iron stores may contribute to IR in obesity by increasing systemic FA availability.

## INTRODUCTION

Accumulating evidence suggests that dysregulated iron homeostasis contributes to metabolic dysfunction in obesity (Gabrielsen *et al.* 2012; Moreno-Navarrete *et al.* 2014; Orr *et al.* 2014), but the mechanisms linking iron and metabolic health remain incompletely understood (Fernández-Real *et al.* 2015). High rates of adipose tissue lipolysis and fatty acid (FA) release into the systemic circulation are associated with insulin resistance in obesity (Van Pelt *et al.* 2017) and some *ex vivo/in vitro* evidence indicates that iron increases lipolysis in adipocytes (Rumberger *et al.* 2004; Chirumbolo *et al.* 2015). There is also some epidemiological evidence linking markers of iron metabolism with plasma FA concentrations (Wlazlo *et al.* 2013), and it has been suggested that iron-mediated lipolysis and FA release may contribute to impaired insulin sensitivity in obesity (Rumberger *et al.* 2004; Chirumbolo *et al.* 2015; Wlazlo *et al.* 2013). However, the relationship between iron and *in vivo* FA release has not been examined. The purpose of this study was to determine if plasma ferritin concentration ([ferritin]), a marker of total body iron stores (Worwood 2007), is positively associated with elevated rates of FA release from adipose tissue in obese, premenopausal women.

## METHODS

### *Ethical Approval*

This study was part of a larger investigation of the relationship between FA mobilization and insulin resistance in obese adults. Some of this study's methods have been reported elsewhere (Van Pelt *et al.* 2017) but are briefly repeated here for convenience. All findings reported in this paper are novel. This study conformed to the standards set by the latest version of the Declaration of Helsinki, was registered at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT01452048), and was approved by the University of Michigan Institutional Review Board (HUM00051537). All participants provided written, informed consent.

We studied 20 obese, premenopausal women with plasma [ferritin] within the clinically-normal range (12-200 ng/mL; Worwood 2007). Participants were weight-stable for  $\geq 6$  months, not pregnant or breastfeeding, and not taking medications/supplements known to affect their metabolism. Participants were studied after an overnight fast during the follicular phase of their menstrual cycle. We collected a baseline blood sample and a subcutaneous abdominal adipose tissue sample, under local anesthetic (Van Pelt *et al.* 2017). FA rate of appearance into systemic circulation (FA Ra) was assessed using  $^{13}\text{C}$  palmitate isotope dilution as detailed elsewhere (Van Pelt *et al.* 2017). Briefly, after collecting the baseline blood and adipose tissue samples,  $^{13}\text{C}$  palmitate was infused at a rate of  $0.04 \mu\text{mol/kg/min}$  for 1 hour. After 45 minutes, we collected 3 blood samples separated by 5 minutes for the determination of the tracer-tracee ratio (TTR) of  $^{13}\text{C}/^{12}\text{C}$  palmitate in plasma for subsequent FA Ra calculations (Patterson *et al.* 1998). Insulin resistance was assessed using a 2-hour primed, hyperinsulinemic-euglycemic clamp—insulin was infused at a rate of  $100 \text{ mU/m}^2/\text{min}$  and insulin sensitivity (the inverse of insulin resistance) was determined as the steady-state glucose infusion rate at the end of the clamp period divided by fat free mass (assessed via dual-energy X-ray absorptiometry).

## *Analytical Methods*

Hemoglobin concentration ([hemoglobin]) and hematocrit were assessed by the University of Michigan Pathology Laboratory. Fasting plasma concentrations of glucose, triglycerides, and cholesterol were measured using colorimetric assays and fasting plasma insulin concentration was measured via radioimmunoassay (Van Pelt *et al.* 2017). Enzyme-linked immunosorbent assays were used for the measurement of plasma concentrations of ferritin (Abcam Ab108837), high-sensitivity C-reactive protein ([CRP], Calbiotech CR120C), soluble transferrin receptor ([sTfr], R&D Systems DTFR1), and hepcidin ([hepcidin], R&D Systems DHP250). For our FA Ra analysis, palmitate TTR, as well as plasma concentrations of palmitate and total FA were all determined using GC/MS (Patterson *et al.* 1998; Patterson *et al.* 1999). Palmitate Ra was calculated from TTR using the steady-state Steele equation (Steele 1959) and FA Ra was calculated by dividing palmitate Ra by the fractional contribution of palmitate to total FA concentration. Standard immunoblotting techniques (Van Pelt *et al.* 2017) were used to quantify the protein abundance of hormone sensitive lipase (HSL; #4107 Cell Signaling), phosphorylated HSL (p-HSL<sup>ser660</sup>; #4126 Cell Signaling), adipose triglyceride lipase (ATGL; #2138 Cell Signaling), and phosphorylated ATGL (p-ATGL<sup>ser406</sup>, kind gift of Dr. Matthew Watt, University of Melbourne). The ATGL antibody recognized a doublet of ~50 and 54 kDa, as has been reported in previous studies (Wang *et al.* 2013; Schreiber *et al.* 2017). A single box was drawn around both bands for ATGL quantification. Protein expression was normalized to total protein stain (Memcode, Thermofisher).

## *Statistics*

All data are presented as mean±SD. Non-normally distributed variables ([sTfr], [Triglycerides], and p-HSL protein expression) were log-transformed prior to statistical analyses. Simple and multiple linear regressions were performed to examine relationships between variables. For group comparisons

between the highest and lowest tertiles of plasma [ferritin], homogeneity of variance was tested (Levene's test) and unpaired t-tests were performed. The level of significance was set at  $p \leq 0.05$  (SPSS version 24).

## RESULTS

### *Plasma [Ferritin] and Group Stratification*

Plasma [ferritin] in our subjects ranged from 23-197 ng/mL, which is within the clinically normal range (Worwood 2007). We stratified subjects into tertiles for comparisons between subjects with high-normal plasma [ferritin] ("High-ferritin";  $144 \pm 28$  ng/ml;  $n=6$ ) vs. low-normal plasma [ferritin] ("Low-ferritin";  $36 \pm 13$  ng/mL;  $n=6$ ). The High-ferritin and Low-ferritin groups were well-matched for age, anthropometric characteristics, and fasting plasma concentrations of glucose, insulin, triglycerides, and cholesterol (Table 1). By design, there was a large (~4-fold) difference in plasma [ferritin] between groups. Hepcidin, a liver-secreted hormone described as the master regulator of iron homeostasis, increases in response to high iron stores (Coffee & Ganz 2017); consistent with this, we found that plasma [hepcidin] was more than 5-fold greater in High-ferritin vs. Low-ferritin. Systemic inflammation can influence [ferritin] and [hepcidin] but plasma [CRP] did not differ between groups, suggesting that the difference in plasma [ferritin] between groups reflects a large difference in body iron stores without a difference in a key marker of systemic inflammation. Basic markers of erythropoiesis ([hemoglobin], hematocrit, and [sTfr]) were also similar between groups (Table 1).

### *Fatty Acid Mobilization*

FA Ra ( $\mu\text{mol/kg fat mass/min}$ ) was more than 80% greater in High-ferritin vs. Low-ferritin ( $p=0.02$ ; Figure 1A). The large between-group difference in FA Ra remained significant when

expressed in absolute terms ( $696 \pm 191$  vs.  $413 \pm 133$   $\mu\text{mol}/\text{min}$ ,  $p=0.01$ ) or normalized to fat-free mass ( $13.7 \pm 3.6$  vs.  $8.6 \pm 2.0$   $\mu\text{mol}/\text{kg}/\text{min}$ ,  $p=0.01$ ). Accompanying the greater FA Ra in High-ferritin vs. Low-ferritin, total protein abundance of HSL and ATGL and the ratio of p-HSL<sup>ser660</sup>:HSL (a marker of elevated lipolytic activation) were all significantly greater in High-ferritin ( $p < 0.05$ ; Figure 1B). There were no differences in the ratio of p-ATGL<sup>ser406</sup>:ATGL (Figure 1B). Across all 20 subjects, plasma [ferritin] was significantly correlated with FA Ra ( $r=0.65$ ;  $p=0.002$ ; Figure 1C). Importantly, using multiple regression analyses, plasma [ferritin] remained independently correlated with FA Ra even when BMI and [CRP] were included as covariates (overall model  $R=0.67$ ,  $p=0.02$ ; [ferritin]  $r_{\text{partial}}=0.67$ ,  $p=0.003$ ; BMI  $r_{\text{partial}}=-0.073$ ,  $p=0.78$ ; [CRP]  $r_{\text{partial}}=-0.13$ ,  $p=0.62$ ).

### *Insulin Sensitivity*

Whole-body insulin sensitivity was nearly 40% lower in High-ferritin vs. Low-ferritin ( $p=0.02$ ; Figure 1D). Across all 20 subjects, plasma [ferritin] was negatively correlated with insulin sensitivity ( $r=-0.57$ ,  $p=0.008$ ; Figure 1E). Using multiple regression analyses, plasma [ferritin] remained independently correlated with insulin sensitivity when BMI and [CRP] were included as covariates (overall model  $R=0.69$ ,  $p=0.02$ ; [ferritin]  $r_{\text{partial}}=-0.62$ ,  $p=0.01$ ; BMI  $r_{\text{partial}}=-0.28$ ,  $p=0.28$ ; [CRP]  $r_{\text{partial}}=-0.16$ ,  $p=0.53$ ).

## **DISCUSSION**

The major novel finding of this study was that plasma [ferritin] was linked with elevated FA Ra in obese, premenopausal women. These data are the first to demonstrate a relationship between iron stores and *in vivo* FA mobilization. Importantly, our findings also suggest that an elevation in systemic FA mobilization in obese adults with relatively high plasma [ferritin] may contribute to

whole-body insulin resistance. Together, these findings suggest that iron stores influence FA metabolism and insulin resistance in obesity, even among individuals with clinically-normal plasma [ferritin].

Circulating [ferritin] is widely used as a biomarker of body iron stores in clinical and research settings (Worwood 2007). However, it is known that systemic inflammation can augment plasma [ferritin] (Gabay & Kushner 1999), which can influence the interpretation of [ferritin] as a marker of body iron stores. For this reason, it is common to assess circulating [CRP] in conjunction with [ferritin] to determine if observed [ferritin] patterns are driven by inflammation. In the present study, we found no difference in [CRP] between High-ferritin and Low-ferritin, and the relationships between [ferritin] and FA Ra and insulin resistance persisted after controlling for [CRP] in multiple regression analyses. Importantly, the relationship between [ferritin] and insulin resistance has repeatedly been shown to remain independent of [CRP] (Wlazlo *et al.* 2015; Jehn *et al.* 2004). We recognize that [CRP] is only one marker of systemic inflammation and we cannot completely dismiss the possible influence of inflammation on [ferritin] in our subjects.

The mechanisms linking iron and insulin resistance remain incompletely understood, but our findings suggest that iron-mediated FA mobilization may be a key underlying mechanism. Previous studies reported that *ex vivo* and *in vitro* treatment of murine adipocytes with iron increased glycerol release (Rumberger *et al.* 2004; Chirumbolo *et al.* 2015), suggesting the possibility that iron may directly or indirectly activate ATGL and/or HSL, the two primary enzymes catalyzing triglyceride hydrolysis (i.e., lipolysis). Gene expression of HSL was recently reported to be significantly increased (and the increase in ATGL expression was nearly statistically significant) in mice after four weeks of dietary iron supplementation (Katsumura *et al.* 2017) but to our knowledge, the influence of iron on lipase protein activation/abundance has not been previously examined. Our findings that total protein abundance of both HSL and ATGL and the ratio of p-HSL<sup>ser660</sup>:HSL were significantly greater in High-ferritin vs. Low-ferritin suggest that iron may increase lipase protein abundance and activation.



Iron is a potent inducer of reactive oxygen species (ROS), which have been found to increase adipocyte HSL activation *in vitro* (Krawczyk *et al.* 2012). Based on these findings, our working hypothesis is that elevated iron increases ROS signaling, thereby increasing lipase activity and FA Ra, resulting in impaired insulin sensitivity.

Our cross-sectional study design enabled us to compare obese subjects with widely differing iron stores that were otherwise well-matched. We hypothesize that iron stimulates lipolysis, resulting in elevated FA Ra, but we cannot rule out the possibility that the converse is true (i.e., elevated FA Ra may increase iron uptake and storage) or that the association between [ferritin] and FA Ra may be mediated by other factors. Additional studies are needed to determine whether iron stores and FA Ra are indeed causally related. Future studies are also needed to examine whether the observed relationships between iron, FA mobilization, and insulin resistance in obese, premenopausal women hold true in other populations.

In summary, we have provided the first evidence linking iron stores and *in vivo* FA mobilization. These findings add to the growing body of evidence indicating that iron stores influence metabolic health, even among individuals with normal iron stores. Future studies are warranted to determine if lowering iron stores is a potential countermeasure to reduce FA mobilization and improve insulin sensitivity in obese adults.

## REFERENCES

- Chirumbolo, S., Rossi, A.P., Rizzatti, V., Zoico, E., Franceschetti, G., Girelli, D., & Zamboni, M. (2015). Iron primes 3T3-L1 adipocytes to a TLR4-mediated inflammatory response. *Nutrition* 31, 1266-1274. <http://doi.org/10.1016/j.nut.2015.04.007>
- Coffee, R., & Ganz, T. (2017). Iron homeostasis: an anthropocentric perspective. *J Biol Chem* 292, 12727-12734. <https://doi.org/10.1074/jbc.R117.781823>

- Fernández-Real, J.M., McClain, D., & Manco, M. (2015). Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. *Diabetes Care* 38, 2169-2176. <https://doi.org/10.2337/dc14-3082>
- Gabay, C., & Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. *New Engl J Med* 340, 448-454. <https://doi.org/10.1056/NEJM199902113400607>
- Gabrielsen, J.S., Gao, Y., Simcox, J.A., Huang, J., Thorup, D., Jones, D., ... McClain D.A. (2012). Adipocyte iron regulates adiponectin and insulin sensitivity. *J Clin Invest* 122, 3529-3540. <https://doi.org/10.1172/JCI44421>
- Katsumura, M., Takagi, S., Oya, H., Tamura, S., Saneyasu, T., Honda, K., & Kamisoyama, H. (2017). Effects of dietary heme iron and exercise training on abdominal fat accumulation and lipid metabolism in high-fat diet-fed mice. *Animal Sci J* 88, 1100-1106. <https://doi.org/10.1111/asj.12734>
- Krawczyk, S.A., Haller, J.F., Ferrante, T., Zoeller, R.A., & Corkey, B.E. (2012). Reactive oxygen species facilitate translocation of hormone sensitive lipase to the lipid droplet during lipolysis in human differentiated adipocytes. *PLoS ONE* 4, e34904. <https://doi.org/10.1371/journal.pone.0034904>
- Moreno-Navarrete, J.M., Novelle, M.G., Catalán, V., Ortega, F., Moreno, M., Gomez-Ambrosi, J, ... Fernández-Real J.M. (2014). Insulin resistance modulates iron-related proteins in adipose tissue. *Diabetes Care* 37, 1092-1100. <https://doi.org/10.2337/dc13-1602>
- Orr, J.S., Kennedy, A., Anderson-Baucum, E.K., Webb, C.D., Fordahl, S.C., Erikson, K.M., ... Hasty A.H. (2014). Obesity alters adipose tissue macrophage iron content and tissue iron distribution. *Diabetes* 63, 421-432. <https://doi.org/10.2337/db13-0213>
- Patterson, B.W., Zhao, G., Elias, N., Hackney, D.L., & Klein, S. (1999). Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. *J Lipid Res* 40, 2118-2124.

- Patterson, B.W., Zhao, G., & Klein, S. (1998). Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers. *Metabolism* 47, 706-712. [https://doi.org/10.1016/S0026-0495\(98\)90035-X](https://doi.org/10.1016/S0026-0495(98)90035-X)
- Rumberger, J.M., Peters, T., Burrington, C., & Green, A. (2004). Transferrin and iron contribute to the lipolytic effect of serum in isolated adipocytes. *Diabetes* 53, 2535-2541. <https://doi.org/10.2337/diabetes.53.10.2535>
- Schreiber, R., Diwoky, C., Schoiswohl, G., Feiler, U., Wongsiriroj, N.A. Abdellatif, M, ... Zechner R. (2017). Cold-induced thermogenesis depends on ATGL-mediated lipolysis in cardiac muscle, but not brown adipose tissue. *Cell Metab* 26, 753-763. <https://doi.org/10.1016/j.cmet.2017.09.004>
- Steele, R. (1959). Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann N Y Acad Sci* 82, 420-430.
- Van Pelt, D.W., Guth, L.M., Wang, A.Y., & Horowitz, J.F. (2017). Factors regulating subcutaneous adipose tissue storage, fibrosis, and inflammation may underlie low fatty acid mobilization in insulin-sensitive obese adults. *Am J Physiol Endocrinol Metab* 313, E429-E439. <https://doi.org/10.1152/ajpendo.00084.2017>
- Wang, H., Sreenivasan, U., Gong, D-W., O'Connell, K.A., Dabkowski, E.R., Hecker, P.A., ... Sztalryd C. (2013). Cardiomyocyte specific perilipin 5 over expression leads to myocardial steatosis, and modest cardiac dysfunction. *J Lipid Res* 54, 953-965. <https://doi.org/10.1194/jlr.M032466>
- Wlazlo, N., van Greevenbroek, M.M.J., Ferreira, I., Jansen, E.H.J.M., Feskens, E.J.M., van der Kallen, C.J.H., ... Stehouwer C.D.A. (2013). Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin. *Diabetes Care* 36, 309-315. <https://doi.org/10.2337/dc12-0505>
- Wlazlo, N., van Greevenbroek, M.M.J., Ferreira, I., Jansen, E.H.J.M., Feskens, E.J.M., van der Kallen, C.J.H., ... Stehouwer, C.D.A. (2015). Iron metabolism is prospectively associated with insulin

resistance and glucose intolerance over a 7-year follow-up period: the CODAM study. *Acta Diabetologica* 52, 337-348. <https://doi.org/10.1007/s00592-014-0646-3>

Worwood, M. (2007). Indicators of iron status of populations: ferritin. In: *Assessing the Iron Status of Populations: Including Literature Reviews*. 2nd ed. Geneva, World Health Organization; pp. 31–73.

#### **COMPETING INTERESTS**

The authors have no competing interests to declare.

#### **AUTHOR CONTRIBUTIONS**

The experiments were performed at the University of Michigan. BJR, DWVP, LMG, AL, and JFH contributed to the conception/design of the work. BJR, DWVP, LMG, AL, RAG, CA, KLF, and JFH contributed to acquisition, analysis, or interpretation of data. BJR, DWVP, LMG, AL, RAG, CA, KLF, and JFH contributed to drafting of the work or revising it critically for important intellectual content. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

#### **FUNDING**

This study was supported by grants from the American Diabetes Association (1-16-ICTS-048), United States National Institutes of Health (R01DK077966, T32DK007245, P30DK089503, UL1TR000433), and Canadian Institutes of Health Research (DFS 146190).

**Table 1. Anthropometric and clinical measures in Low-Ferritin vs. High-Ferritin.**

	<b>Low-Ferritin (n = 6)</b>	<b>High-Ferritin (n = 6)</b>	<b>P-Value</b>
Age (years)	34 ± 11	33 ± 7	0.80
Body Mass (kg)	96 ± 11	98 ± 9	0.73
Body Mass Index (kg/m <sup>2</sup> )	35 ± 2	37 ± 3	0.25
Body Fat (%)	51 ± 3	48 ± 6	0.36
Fat Mass (kg)	49 ± 8	47 ± 9	0.73
Fat Free Mass (kg)	47 ± 5	51 ± 6	0.27
Fasting [Glucose] (mM)	4.7 ± 0.5	4.5 ± 0.7	0.61
Fasting [Insulin] (μU/mL)	14 ± 10	18 ± 6	0.40
Fasting [Triglycerides] (mg/dL)	53 ± 20	61 ± 37	0.83
Fasting [Cholesterol] (mg/dL)	159 ± 45	167 ± 16	0.70
Plasma [Ferritin] (ng/mL)	36 ± 13	144 ± 28	0.000007*
Plasma [Hepcidin] (ng/mL)	34 ± 54	184 ± 118	0.02*
Plasma [CRP] (mg/dL)	0.9 ± 0.8	1.2 ± 0.8	0.48
[Hemoglobin] (g/dL)	12.2 ± 1.2	12.4 ± 0.3	0.64
Hematocrit (%)	37 ± 3	37 ± 1	0.91
Plasma [sTfr] (nM)	28 ± 14	19 ± 5	0.21

Data are presented as mean ± SD. \*p≤0.05.

## FIGURE CAPTIONS

**Figure 1.** **A)** Fatty acid rate of appearance (FA Ra) in Low-Ferritin (closed circles) vs. High-Ferritin (open circles). **B)** Relative protein abundance of lipolytic proteins in adipose tissue; data were normalized to total protein stain (Memcode) and expressed relative to the mean of the Low-Ferritin group. Western blot images show all individual data for subjects in the Low-Ferritin and High-Ferritin groups (for each protein, all subjects were run on a single gel with a molecular weight marker after the 4<sup>th</sup> sample). A representative image of the total protein stain is shown. Images were processed using Image J; image adjustments were limited to changes in brightness and contrast to optimize visualization and were performed uniformly on the whole image. **C)** Correlation between plasma [ferritin] and FA Ra across all subjects. **D)** Insulin sensitivity (glucose infusion rate; GIR) in Low-Ferritin vs. High-Ferritin. **E)** Correlation between plasma [ferritin] and insulin sensitivity across all subjects. Data in panels A, B, and D are presented as mean  $\pm$  SD with individual data shown.

\* $p < 0.05$ .

